Last reviewed · How we verify
ShigETEC vaccine
At a glance
| Generic name | ShigETEC vaccine |
|---|---|
| Sponsor | Eveliqure Biotechnologies GmbH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ShigETEC Vaccine Study in Bangladesh (PHASE1)
- Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old (PHASE2)
- Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ShigETEC vaccine CI brief — competitive landscape report
- ShigETEC vaccine updates RSS · CI watch RSS
- Eveliqure Biotechnologies GmbH portfolio CI